In-Vitro Activity of Nano Fluconazole and Conventional Fluconazole against Clinically Important Dermatophytes

Najmossadat MUSAVI BAFRUI 1, *Seyed Jamal HASHEMI HAZAVEH 1,2, Mansour BAYAT 1

1. Department of Microbiology, Faculty of Veterinary Specialized Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran
2. Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

*Corresponding Author: Email: sjhashemi@tums.ac.ir

(Received 11 Aug 2019; accepted 22 Oct 2019)

Abstract
Background: Dermatophytosis is one of the most common fungal infections in humans. Antifungals such as fluconazole are effectively used for treating dermatophytosis; however, drug resistance was observed in many cases. Therefore, a newer treatment strategy is essential.

Methods: This study (Conducted in the Laboratory of the School of Public Health, Tehran University of Medical Sciences, Tehran, Iran in 2018) evaluated the antifungal susceptibility of nano fluconazole compared to conventional fluconazole on dermatophyte isolates using CLSI M38-A2 guidelines. Dermatophyte species isolated from clinical cases of dermatophytosis were identified using PCR sequencing techniques. Zeta potential and size of the nanoparticles containing fluconazole were measured; scanning electron microscope (SEM) was used to determine nano particle structure.

Results: The size of liposomal fluconazole obtained was 88.9 ± 12.14 nm with −20.12 ± 3.8 mV for zeta potential. The encapsulation rate for fluconazole was 75.1 ± 4.2%. MIC50 for the three tested species was 32, 16, and 8 μg/ml for Trichophyton interdigitale, T. rubrum, and Epidermophyton floccosum isolates, respectively. The corresponding values for nano fluconazole were 8 μg/ml for the three tested species.

Conclusion: MIC value for nano-fluconazole was lower than conventional fluconazole in all dermatophytes species tested; therefore, nano-fluconazole could inhibit the growth of dermatophytes better than fluconazole at a lower concentration of the drug.

Keywords: Dermatophyte; Minimum inhibitory concentration; Fluconazole; Nano-particle

Introduction

Dermatophytosis is a common mycotic infection, affecting keratinized tissues such as skin, hair, and nails of humans and animals. Dermatophytes can be classified into three genera: Trichophyton, Microsporum, and Epidermophyton (1). There are about 40 species in these three genera while only 19 species are known as pathogenic. Also, based upon the affected anatomical site of the body, dermatophytosis has been classified clinically into tinea capitis (head), tinea faciei (face), tinea barbae (beard), tinea corporis (body), tinea manuum (hand), tinea cruris (groin), tinea pedis (foot), and tinea unguium (nail) (2, 3).

Although dermatophytosis is not life-threatening, it severely affects the quality of life and imposes significant treatment costs on patients (4). Der-
Matophytosis can easily be eradicated by topical antifungal drugs, while tinea capitis and tinea unguium do not respond well to local treatment and require systemic antifungal agents (5). Although newer oral antifungal agents used for the treatment of invasive and superficial infections have significantly improved efficacy of treatment for many fungal infections, side effects, drug interactions, and resistant organisms have considerably challenged, requiring safer and more effective treatments.

Once drug resistance occurs, it is necessary to use newer antifungal agents. Nanotechnology has been effective in many fields, particularly drug administration. Nanoparticles (NPs) are a newer generation of antimicrobial agents studied significantly in recent years (6). Nanoparticles can improve bioavailability, solubility, and permeability of drugs. Nano-liposomes have many advantages, including improved penetration and diffusion of active ingredients, selective transport of active ingredients, longer release time, and greater stability (7).

Treatment with antifungal agents, particularly fluconazole (FLC), is considered as an effective treatment for some cases of dermatophytosis (8); however, there were challenges such as drug resistance and side effects. Thus, it is necessary to use newer therapeutic strategies.

In the current study, the antifungal activity of nano-fluconazole (nano-FLC) was compared to FLC on some clinically important dermatophytes.

Materials and Methods

Samples
Samples were taken from patients suspected of dermatophytosis, referred to the Mycology Laboratory, Tehran University of Medical Sciences, Tehran, Iran in 2018. The samples (including hair, skin, and nail) were taken, examined by direct microscopy with KOH and cultured on SDA with chloramphenicol and cycloheximide, and then incubated at 28°C for 3 weeks.

Identification of isolates
All the dermatophyte isolates were identified based on microscopic and macroscopic properties and then subjected to molecular identification by sequencing internal transcribed spacer (ITS) regions of ribosomal DNA (rDNA) by panfungal primers ITS 1 (5’-TCC GTA GGT GAA CCT GCG G-3’) and ITS 4 (5’-TCC TCC GCT TAT TGA TAT GC -3’) (9).

Preparation of fluconazole and nano-FLC
Crude powder of FLC (Sigma-Aldrich, Steinheim, Germany) was purchased from Sigma Company. The liposomal formulation of FLC was made by thin-layer film hydration (10). For producing liposomes, 5.12 mg FLC, 5 mg cholesterol, and 50 mg lecithin were used. A thin layer was formed by dissolving these two substances at a rate of 5.12 mg/ml in an organic solvent chloroform-methanol mixture (1:1) containing FLC. The final concentration of drug was 5120 μg/ml. This formulation was transferred to the laboratory for antifungal susceptibility test. The blank liposomal formulation was made without FLC.

Evaluation of physicochemical properties of nano-FLC
Size, morphology, and zeta potential of nano-FLC were evaluated. To calculate particle size, liposomal nanoparticles produced by PCS were evaluated by using photon correlation spectroscopy. For measuring the particle in this device, formulations diluted with distilled water were transferred to the instrument and measured. Zeta potential was measured by a Zetasizer device, based on laser light scattering. Particle size distribution in the device was evaluated based on PDI (polydispersity index). For examining the nano particle structure, scanning electron microscope (SEM) was used. A small quantity of sample was placed on a glass surface (1 × 1 cm). It was then placed inside an incubator at 37°C until the sample was completely dried. Then the particles were coated with gold; images were taken with 20000x and 40000x magnification.

Antifungal susceptibility test
In-vitro antifungal susceptibility was tested following the guidelines of the Clinical and Laboratory Standards Institute (CLSI) M38-A2 manual.

Available at: http://ijph.tums.ac.ir
(11). FLC (Sigma- Aldrich, Steinheim, Germany) and nano-FLC were diluted in standard RPMI 1640 medium (Sigma-Aldrich, St. Louis, MO, USA) buffered to pH 7.0 by 0.165 mol L-1 morpholine propane sulfonic acid buffer with L-glutamine without bicarbonate (MOPS, Sigma-Aldrich, St. Louis, MO, USA) to yield twice their concentrations; they were dispensed into 96-well microdilution trays with a final concentration of 0.25–128 µg/ml for antifungal agents. Plates were stored at -70°C until testing. All isolates were cultured on Potato dextrose agar (PDA, Difco) at least for two weeks at 30°C for sporulation. Sterile normal saline (85%) was added to colonies; the suspension was collected and transferred to a tube. In order to obtain pure conidia, the suspension was filtered by a sterile filter (8µm in diameter; Whatman 40, Sao Paulo, Brazil) and collected in a sterile tube. The concentration of the resulting suspension was set spectrophotometrically (530 nm wavelength) to optical densities (ODs), ranging from 65% to 70% transmission. The inoculum suspensions diluted in RPMI-1640 were buffered (1:50) by MOPS. The final stock inoculum suspensions of each tested isolate was 1–3×10³ colony forming units (CFU)/ml, determined by quantitative colony counts on Sabouraud glucose agar (SGA; Difco). For the tests, 100 ml diluted cell suspension was added to each well. All tests were done in duplicate. After incubation for 60 h at 35°C, plates were read visually; MICs were determined as the lowest concentration of drug that gave approximately 80% inhibition of the growth control. The strains *T. mentagrophytes* (ATCC 4439) and *T. rubrum* (ATCC 4438) were used for quality control.

**Statistical analysis**

Data was analyzed using SPSS software (ver.18, Chicago, IL, USA). MIC distributions were compared in groups for FLC and nano-FLC using Student’s t-test. Differences were statistically significant (two-tailed P-value≤0.05).

**Results**

**Dermatophyte isolates and clinical manifestation**

Out of 312 patients with suspected dermatophytosis referred to mycology laboratory of Tehran University of Medical Sciences and veterinary clinics in Tehran, 80 dermatophytes were isolated by direct examination and culture of 42 males (52.5%) and 38 females (47.5%). The prevalence of dermatophytosis was 25.6% in this study. *Tinea pedis* (35.0%) was the most common type of dermatophytosis. (Table 1). The distribution of all isolates is summarized in Table 2.

| Clinical manifestation | Age groups (years) | Gender |  
|------------------------|-------------------|--------|
|                        | ≤10 | 10-20 | 21-30 | 31-40 | 41-50 | >50 | Male (%) | Female (%) | Total (%) |
| Tinea pedis            | -   | -     | 4     | 5     | 8     | 11  | 17 (21.25) | 11 (13.75) | 28 (35.0) |
| Tineacorporis          | 1   | 2     | 5     | 4     | 3     | 3   | 7 (8.75)   | 11 (13.75) | 18 (22.5) |
| Tineaungium            | -   | 1     | 1     | 2     | 3     | 7   | 8 (10.0)   | 6 (7.5)     | 14 (17.5) |
| Tineacruris            | -   | 1     | 3     | 2     | 3     | 4   | 6 (7.5)    | 7 (8.75)    | 13 (16.25) |
| Tinea capitis          | 1   | 2     | -     | -     | -     | -   | 2 (2.5)    | 1 (1.25)    | 3 (3.75)  |
| Tinea faciei           | 1   | -     | -     | -     | 1     | -   | - 1 (1.25) | - 1 (1.25)  | 2 (2.5)   |
| Tinea manuum           | -   | -     | -     | -     | 1     | 1   | 1 (1.25)   | 1 (1.25)    | 2 (2.5)   |
| Total                  | 3   | 6     | 13    | 13    | 19    | 26  | 42 (52.5)  | 38 (47.5)   | 80 (100)  |
Table 2: Distribution of all isolates in various clinical manifestation

| Clinical manifestation Isolates | Tinea pedis (%) | Tinea corporis (%) | Tinea unguium (%) | Tinea cruris (%) | Tinea capitis (%) | Tinea faciei (%) | Tinea manuum (%) | Total (%) |
|--------------------------------|-----------------|-------------------|------------------|-----------------|------------------|-----------------|-----------------|-----------|
| T. interdigitale               | 14 (17.5)       | 7 (8.75)          | 5 (6.25)         | 2 (2.5)         | -                | -               | -               | 28 (35)   |
| T. rubrum                      | 8 (10.0)        | 3 (3.75)          | 9 (11.25)        | 4 (5.0)         | -                | -               | 1 (1.25)        | 25 (31.25) |
| E. floccosum                   | 3 (3.75)        | 1 (1.25)          | -                | 7 (8.75)        | -                | 1 (1.25)        | -               | 12 (13.75) |
| T. verrucosum                  | 2 (2.5)         | 1 (1.25)          | -                | -               | 1 (1.25)         | -               | -               | 4 (5.0)   |
| M. canis                       | -               | 4 (5.0)           | -                | -               | -                | -               | -               | 4 (5.0)   |
| T. tonsurans                   | -               | 1 (1.25)          | -                | -               | 1 (1.25)         | 1 (1.25)        | -               | 3 (3.75)   |
| M. gypseum                     | 1 (1.25)        | 1 (1.25)          | -                | -               | -                | -               | -               | 1 (1.25)   |
| T. schoenleinii                | -               | -                 | -                | 1 (1.25)        | -                | -               | -               | 1 (1.25)   |
| Total                          | 28 (35.0)       | 18 (22.5)         | 14 (17.5)        | 13 (16.25)      | 3 (3.75)         | 2 (2.5)         | 2 (2.5)         | 80 (100)   |

Nano-FLC properties

In this section, particle size, encapsulation rate, zeta potential, and polydispersity index of liposomal formulation of FLC are determined. Zeta potential was calculated for FLC liposomal formulation (20.12 ± 3.8 mV). Diagram of zeta potential of liposomal formulation containing FLC is shown in Fig. 1. Fig. 2 shows the result of scanning electron microscopy considering particle size distribution of nano-liposomes containing FLC. Nanoparticles are spherical (88.9 ± 12.14 nm in size). The sizes obtained from electron microscope confirmed the result of the zetasizer device. Moreover, the values obtained for PDI and Encapsulation rate were 0.448 and 75.4 ± 1.2, respectively.

Fig. 1: Curve of zeta potential of Nano-FLC

Fig. 2: Image of nano particles with scanning electron microscope (SEM)

Antifungal susceptibility test

MIC_{50}, MIC_{90}, and MIC values of 80 clinical dermatophytes were determined. Because of the limited number of M. canis, T. tonsurans, M. gypseum, T. verrucosum and T. schoenleinii isolates, MIC_{50} and MIC_{90} were not calculated for these species. As shown in Table 3, MIC value of all dermatophytes species for nano-FLC were lower than conventional FLC. T. schoenleinii has the highest MIC value (128 μg/ml) compared to other isolates.

Available at:  http://ijph.tums.ac.ir
Table 3: In-vitro antifungal susceptibilities of 80 clinical isolates of dermatophytes against FLC and nano-FLC

| Dermatophyte species       | Antifungal agent | MIC\(^b\) range (μg/ml) | MIC\(_{50}\)\(^c\) (μg/ml) | MIC\(_{90}\)\(^d\) (μg/ml) | P-value\(^e\) |
|----------------------------|------------------|--------------------------|----------------------------|--------------------------|---------------|
| *T. interdigitale* (n=28)  | FLC\(^a\)        | 4-64                     | 32                         | 64                       | <0.01         |
|                            | nano-FLC         | 1-32                     | 8                          | 16                       |               |
| *T. rubrum* (n=25)         | FLC\(^a\)        | 4-64                     | 16                         | 32                       | <0.01         |
|                            | nano-FLC         | 2-16                     | 8                          | 16                       |               |
| *E. floccosum* (n=12)      | FLC\(^a\)        | 8-32                     | 8                          | 16                       | <0.01         |
|                            | nano-FLC         | 2-16                     | 8                          | 16                       |               |
| *T. verrucosum* (n=4)      | FLC\(^a\)        | 32-64                    | -                          | -                        | <0.01         |
|                            | nano-FLC         | 8-32                     | -                          | -                        |               |
| *M. canis* (n=4)           | FLC\(^a\)        | 4-16                     | -                          | -                        | <0.01         |
|                            | nano-FLC         | 1-8                      | -                          | -                        |               |
| *T. tonsurans* (n=3)       | FLC\(^a\)        | 8-32                     | -                          | -                        | <0.01         |
|                            | nano-FLC         | 8-16                     | -                          | -                        |               |
| *M. gypseum* (n=3)         | FLC\(^a\)        | 16-32                    | -                          | -                        | <0.01         |
|                            | nano-FLC         | 8                        | -                          | -                        |               |
| *T. schoenleinii* (n=1)    | FLC\(^a\)        | 128                      | -                          | -                        | <0.01         |
|                            | nano-FLC         | 64                       | -                          | -                        |               |
| **Total (n=80)**           | FLC\(^a\)        | 1-128                    | 16                         | 32                       | <0.01         |
|                            | nano-FLC         | 1-64                     | 8                          | 16                       |               |

\(^a\)FLC: Fluconazol; \(^b\)MIC: Minimum inhibitory concentration; \(^c\)MIC\(_{50}\): minimal concentration that inhibits 50% of isolates; \(^d\)MIC\(_{90}\): minimal concentration that inhibits 90% of isolates; \(^e\)P-value: probability value.

Discussion

In this study, the antifungal activity of nano-FLC was studied on clinical dermatophyte isolates. As shown in Table 1, the most common cases of dermatophyte species were tinea pedis (35%) and the least was tinea manum (2.5%) and tinea faciei (2.5%). Similar to other studies in Iran, *T. interdigitale* and *T. rubrum* were the most prevalent species (3, 12-14). All dermatophyte isolates were identified using sequencing the ribosomal DNA (rDNA), internal transcribed spacer (ITS) regions. The exact identification of species is essential for epidemiological studies and appropriate treatment.

As drug resistance occurs, it seems necessary to find newer and more effective antifungal agents to overcome the resistant strains. Azoles have a low solubility in water and, therefore, their bioavailability is low. Usually, the drug is distributed unevenly in the body, and some cells take part in metabolizing the drug in the blood system. The drug is partially removed from the system before it is used. So far, some protocols have been used for the modification of antifungal agents. New drug industries have taken a step in production and administration of modern drug systems. The most important of these systems, widely used today, are hydrogels, nanofibers, nanoliposomes, niosomes, and nano-dendrimer (15).

Liposomes and nano liposomes coated with polymers have good properties, such as better adhesion to mucosal cells and better permeability than in the gastrointestinal. Research on calcitonin showed evidence of this claim (16). For the treatment of cutaneous fungal infections, permeation of the selected drug into the deeper layers of the skin is necessary (17). The small size of the lipid nano particles improves the presence of nano particles in direct contact with stratum corneum and ensures entry of the encapsulated drugs into the skin (18). In the present study, the liposomal formulation was developed and demonstrated more effective antifungal properties on dermatophyte species compared with the conventional form of fluconazole.

Particle size, zeta potential and drug-loaded was 88.9 ± 12.14 nm, 20.12 ± 3.8 mV and 75.4 ± 1.2%, respectively. Particle size and distribution width is often one of the most important quality-

Available at:  [http://ijph.tums.ac.ir](http://ijph.tums.ac.ir)
related parameters which affect other macroscopic properties of the nano-particle. Particles larger than 1 µm and an increase in their number can show their physical instability (19). Zeta potential is an important factor in determining the stability of the colloidal system and is the best indicator for determining the surface electric status of dispersions. In this study, the particle size of less than 1 µm and zeta potential of 20.12 ± 3.8 mV indicated and confirmed the stability of the formulated nano-FLC.

To investigate the effect of new antifungal compounds, in-vitro susceptibility tests and animal models are required. In this study, antifungal susceptibility test on clinical dermatophyte isolate of standard broth microdilution method was evaluated for conventional FLC and nano-FLC according to CLSI M38-A guidelines. MIC value for nano-FLC was lower than FLC in all dermatophyte species tested. Lower MIC was reported for nano-FLC against Aspergillus species (7). Lipids can contribute to better penetration of fluconazole in the skin (20). Nano-FLC against Candida-resistant and sensitive species showed better antifungal activity than the common form of the drug (21). Many studies have shown the antimicrobial effects of FLC (13, 22, 23), but the literature lacks studies on the effects of nano-FLC against dermatophytes.

The primary significance of this study is that nano-FLC could inhibit the growth of dermatophytes better than conventional FLC. To our knowledge, this is the first study to apply nano-FLC successfully to dermatophytes.

**Conclusion**

Liposomal nano particles prepared by thin-layer hydration containing fluconazole have a small and appropriate particle size and a polydispersity index of about 0.4 and a high loading percentage. Spherically and particle size uniformity of the liposomes prepared by scanning electron microscopy was confirmed. Studies on antifungal effects of this formulation in-vitro show that these nanoparticles have acceptable antifungal effects for the reasons discussed earlier compared to the free form of the drug.

**Ethical considerations**

Ethical issues (Including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors.

**Acknowledgements**

The authors wish to thank the support of Tehran University of Medical Sciences Also, we are gratefully acknowledged to Department of Microbiology, Faculty of Veterinary Specialized Sciences, Science and Research Branch, Islamic Azad University for continued cooperation.

**Conflict of interest**

The authors declare that there is no conflict of interest.

**References**

1. Merz WG, Hay RJ (2005). *Topley and Wilson's Microbiology and Microbial Infections: Medical Mycology*. Hodder Arnold.
2. Heidrich D, Garcia MR, Ottonelli Stopiglia CD, et al (2015). A 16-year retrospective study in a metropolitan area in southern Brazil. *J Infect Dev Countr*, 9 (8):865-71.
3. Farokhipor S, Ghiasian SA, Nazeri H, et al (2018). Characterizing the clinical isolates of dermatophytes in Hamadan city, Central west of Iran, using PCR-RLFP method. *Journal de Mycologie Medicale*, 28 (1):101-105.
4. Gupta AK, Cooper EA (2008). Update in antifungal therapy of dermatophytosis. *Mycopathologia*, 166 (5-6):353-67.
5. Rezaei-Matehkolaei A, Khodavaisy S, Alshahni MM, et al (2018). In-vitro antifungal activity of novel triazole efinaconazole and five comparators against dermatophyte isolates. *Antimicrob Agents Chemother*, 62 (5):e02423-17.

Available at: [http://ijph.tums.ac.ir](http://ijph.tums.ac.ir)
6. Parsameher N, Rezaei S, Khodavaisy S, et al (2017). Effect of biogenic selenium nanoparticles on ERG11 and CDR1 gene expression in both fluconazole-resistant and susceptible Candida albicans isolates. Curr Med Mycol, 3 (3):16-20.

7. Sarrafi MR, Hashemi SJ, Rezaei S, et al (2018). In vitro Evaluation of the Effects of Fluconazole and Nano-Fluconazole on Aspergillus flavus and A. fumigatus Isolates. Archive of SID Jundishapur J Microbiol, 11 (6):e57875.

8. Gupta AK, Cooper EA (2008). Dermatophytosis (Tinea) and other superficial fungal infections. Diagnosis and treatment of human mycoses, 355-381.

9. Innis MA, Celfand DH, Sninsky JJ, et al (2012). PCR protocols: a guide to methods and applications. Academic Press.

10. Ola H, Yahia SA, El-Gazayerly ON (2010). Effect of formulation design and freeze-drying on properties of fluconazole multilamellar liposomes. Saudi Pharm J, 18 (4):217-24.

11. John H (2008). Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, approved standard. M38-A2. Clin Lab Stand Inst, 28 (16):1-35.

12. Rafat Z, Hashemi SJ, Saboor-Yaraghi AA, et al (2019). A systematic review and meta-analysis on the epidemiology, casual agents and demographic characteristics of onychomycosis in Iran. J Mycol Med, 29 (3):265-272.

13. Ansari S, Hedayati MT, Zomorodian K, et al (2016). Molecular characterization and in-vitro antifungal susceptibility of 316 clinical isolates of dermatophytes in Iran. Myopathologia, 181 (1-2):89-95.

14. Falahat M, Akhlaghi L, Lari AR, et al (2003). Epidemiology of dermatophytoses in an area south of Tehran, Iran. Myopathologia, 156 (4):279-87.

15. Moghimipour E, Handali S (2013). Liposomes as drug delivery systems: properties and applications. Res J Pharm Biol Chem Sci, 4 (1):169-85.

16. Takeuchi H, Sugihara H (2010). Absorption of calcitonin in oral and pulmonary administration with polymer-coated liposomes. Yakugaku Zasshi, 130 (9):1135-42.

17. Samnani A, Shahwali V, Bhowmick M, et al (2012). Design and evaluation of ultradisperse soft elastic nano vesicule ethosomes for dermal delivery. International Journal of Biomedical and Advance Research, 3 (02):111-7.

18. Ghadiri M, Fatemi S, Vatanara A, et al (2012). Loading hydrophilic drug in solid lipid media as nanoparticles: statistical modeling of entrapment efficiency and particle size. International Journal of Pharmaceutics, 424 (1-2):128-37.

19. Patrawale V, Ambarkhane A (2003). Study of solid lipid nanoparticles with respect to particle size distribution and drug loading. Pharmazie, 58 (6):392-5.

20. Gupta M, Tiwari S, Vyas SP (2013). Influence of various lipid core on characteristics of SLNs designed for topical delivery of fluconazole against cutaneous candidiasis. Pharm Dev Technol, 18 (3):550-9.

21. Asadi M, Hamishehkar H, Hashemi SJ (2017). Evaluation of antifungal effects of nanoliposomal fluconazole against Fluconazole susceptible and resistant Candida species isolated from patients in vitro and comparison with common fluconazole. 11th International Symposium on Antimicrobial Agents and Resistence (ISAAR)/3rd International Interscience Conference on Infection and Chemotherapy (ICIC).

22. Baghi N, Shokohi T, Badali H, et al (2016). In-vitro activity of new azoles luliconazole and lanoconazole compared with ten other antifungal drugs against clinical dermatophyte isolates. Med Mycol, 54 (7):757-63.

23. Deng SW, Ansari S, Ilkit M, et al (2017). In vitro antifungal susceptibility profiles of 12 antifungal drugs against 55 Trichophyton schoenleinii isolates from tinea capitis favosa patients in Iran, Turkey, and China. Antimicrob Agents Chemother, 61:e01753-16.